Hybrid L24 New Enrollment Post Approval Study (HNE)
Nucleus Hybrid L24 Implant System: New Enrollment Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Arizona Ear Center
-
-
California
-
Sacramento, California, United States, 95823
- Kaiser Permanente South Sacramento
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Hospitals
-
Englewood, Colorado, United States, 80113
- Rocky Mountain Ear Center
-
Englewood, Colorado, United States, 80110
- Denver Ear Associates
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Illinois
-
Northbrook, Illinois, United States, 60062
- Northshore University Health System
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, United States, 21204
- Greater Baltimore Medical Center
-
-
Massachusetts
-
Burlington, Massachusetts, United States, 01803
- Lahey Hospital and Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Farmington Hills, Michigan, United States, 48334
- Michigan Ear Institute
-
-
Missouri
-
Kansas City, Missouri, United States, 64111
- Midwest Ear Institute
-
-
Ohio
-
Cincinnati, Ohio, United States, 45219
- The University of Cincinnati
-
Westerville, Ohio, United States, 43082
- Ohio Ear Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15212
- Pittsburgh Ear Associates
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
San Antonio, Texas, United States, 78258
- Ear Institute of Texas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Ear to Be Implanted:
- Normal to moderate hearing loss in the low frequencies with severe to profound mid to high frequency hearing loss in the ear to be implanted
- CNC word recognition of 10-60% in the ear to be implanted
Contralateral Ear:
- Moderately severe to profound mid to high frequency hearing loss in the contralateral ear
- CNC word recognition equal to or better than that in the ear to be implanted but not more than 80% correct
Exclusion Criteria:
- not proficient in English
- unwilling and/or unable to comply with the test protocol
- deafness due to lesions of the acoustic nerve or central auditory pathway.
- active middle-ear disease, with or without tympanic membrane perforation.
- absence of cochlear development.
- duration of severe to profound hearing loss of 30 years or greater
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nucleus Hybrid L24 Implant
Adults age 18 and over who meet FDA criteria for unilateral implantation with the Nucleus Hybrid L24 Implant.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Consonant-Nucleus-Consonant (CNC) Word Recognition in Quiet for the Two Listening Conditions: Implant Ear Alone and When Using Both Ears Together From Pre-operatively Through 3 Years Post-activation of the Device
Time Frame: From pre-operatively through 3 years post-activation of the device
|
The CNC Words test consists of 10 recorded lists of 50 monosyllabic words in CD format.
For this study, two lists will be administered in quiet at a level equal to 60 dBA in the sound field and recorded as a total number of words correct, which will be expressed as a percentage correct for this study.
The CNC word test has a score range of 0-100% with higher values indicating better scores.
|
From pre-operatively through 3 years post-activation of the device
|
|
Number of Device or Procedure Related Adverse Events
Time Frame: Up to 5 years post-activation of the device
|
Up to 5 years post-activation of the device
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in AzBio Sentence Recognition in Noise in the Best Unilateral Condition
Time Frame: Pre-operatively, up to 3 years post-activation of the device
|
The AzBio Sentence Tests consists of 15 lists of 20 sentences each.
AzBio sentences are spoken by different talkers in a conversational style with limited contextual cues that the listener can use to predict or 'fill in' unintelligible words.
Each list includes 5 sentences from 4 different male and female speakers.
Each word in the sentence counts toward the overall score and the resulting score is presented in percent correct.
The AzBio sentence test has a score range of 0-100% with higher values indicating better scores.
|
Pre-operatively, up to 3 years post-activation of the device
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Brian Kaplan, MD, Greater Baltimore Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAM-5573-HYB-PMA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.